A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes,Armando Santoro,Margaret A. Shipp,Pier Luigi Zinzani,John M. Timmerman,Stephen M. Ansell,Philippe Armand,Michelle A. Fanale,Voravit Ratanatharathorn,John Kuruvilla,Jonathon B. Cohen,Graham P. Collins,Kerry J. Savage,Marek Trneny,Kazunobu Kato,Benedetto Farsaci,Susan M. Parker,Scott J. Rodig,Margaretha G.M. Roemer,Azra H. Ligon,Andreas Engert +20 more
TL;DR: Nivolumab resulted in frequent responses with an acceptable safety profile in patients with classical Hodgkin's lymphoma who progressed after autologous stem-cell transplantation and brentuximab vedotin, and might be a new treatment option for a patient population with a high unmet need.
Journal ArticleDOI
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Jordi Bruix,Jean-Luc Raoul,Morris Sherman,Vincenzo Mazzaferro,Luigi Bolondi,Antonio Craxì,Peter R. Galle,Armando Santoro,Michel Beaugrand,Angelo Sangiovanni,Camillo Porta,Guido Gerken,Jorge A. Marrero,Andrea Nadel,Michael Shan,M. Moscovici,D. Voliotis,Josep M. Llovet +17 more
TL;DR: The SHARP trial as discussed by the authors showed that sorafenib consistently improved median OS and DCR compared with placebo in patients with advanced HCC, irrespective of disease etiology, baseline tumor burden, performance status, tumor stage and prior therapy.
Journal ArticleDOI
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Thomas Yau,Yoon-Koo Kang,Tae-You Kim,Anthony B. El-Khoueiry,Armando Santoro,Bruno Sangro,Ignacio Melero,Masatoshi Kudo,Ming Mo Hou,Ana Matilla,Francesco Tovoli,Jennifer J. Knox,Aiwu Ruth He,Bassel F. El-Rayes,Mirelis Acosta-Rivera,Ho Yeong Lim,Jaclyn Neely,Yun Shen,Tami Wisniewski,Jeffrey Anderson,Chiun Hsu +20 more
TL;DR: The manageable safety profile and promising response rates observed in this study support further investigation of nivolumab plus ipilimumab as a treatment option for this patient population.
Journal ArticleDOI
Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
Federico Cappuzzo,Antonio Marchetti,Margaret Skokan,Elisa Rossi,Sujatha Gajapathy,Lara Felicioni,Maela Del Grammastro,Maria Grazia Sciarrotta,F Buttitta,Matteo Incarbone,Luca Toschi,Giovanna Finocchiaro,Annarita Destro,Luigi Terracciano,Massimo Roncalli,Marco Alloisio,Armando Santoro,M. Varella-Garcia +17 more
TL;DR: MET increased gene copy number is an independent negative prognostic factor in surgically resected NSCLC and EGFR gene gain does not impact survival after resection.
Journal ArticleDOI
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study
Armando Santoro,Lorenza Rimassa,Ivan Borbath,Bruno Daniele,Stefania Salvagni,Jean-Luc Van Laethem,Hans Van Vlierberghe,Jörg Trojan,Frank T. Kolligs,Alan Weiss,Steven A. Miles,Antonio Gasbarrini,Monica Lencioni,Luca Cicalese,Morris Sherman,Cesare Gridelli,Peter Buggisch,Guido Gerken,Roland M. Schmid,Corrado Boni,Nicola Personeni,Ziad Hassoun,Giovanni Abbadessa,Brian Schwartz,Reinhard von Roemeling,Maria Lamar,Yinpu Chen,Camillo Porta +27 more
TL;DR: Tivantinib could provide an option for second-line treatment of patients with advanced hepatocellular carcinoma and well-compensated liver cirrhosis, particularly for patients with MET-high tumours.